What's in a name? A timely question in Australian medicine just now. The Therapeutic Goods Administration (TGA) has decreed a change of name, of varying degrees of complexity, of some 200 drugs as of April 2016, with a four year changeover period.
The global reference for medicine ingredient names is the International Nonproprietary Name (INN) system, developed by the World Health Organization in the 1950s and maintained by a committee of member states, of which Australia is one 1 . The TGA has adopted INNs for new ingredient names since 2002; older drug names have now been converted, en masse, to INN terminology.
With the notable exception of adrenaline and noradrenaline (which for a variety of reasons will be officially known and labelled as adrenaline [epinephrine] and noradrenaline [norepinephrine] in perpetuity), drugs which have significant changes to their names will be labelled with both new and old names until 2020. Interestingly, we get to keep paracetamol, as it is the INN; acetaminophen is classed as a USAN (United Stated Adopted Name) 2 .
Many of the name changes apply to drugs used in anaesthesia, intensive care, and pain medicine. The Journal is not obliged to adopt the new nomenclature, and indeed the initial response from other Australian medical publications has been mixed.
Those, such as this author, who revere tradition and the English language (medical or otherwise) may be horrified, or see this as further evidence of the perceived dumbing down of medicine in general and anaesthesia in particular. One envisages that anaesthetists on the more pronounced end of the obsessive-compulsive spectrum will decline to write up (or to write down) patients' regular medications altogether, just to avoid colecalciferol, colestyramine and ciclosporin. And then there's dexamfetamine and indometacin.
It is rather unfortunate then, that the arguments in favour of conformity have considerable merit.
Firstly, the primary purpose of this endeavour is to increase medication safety through the adoption of global nomenclature. We as clinicians practise in a multicultural and internationally mobile milieu, which includes those who dispense, administer and consume the drugs we prescribe, be they junior colleagues, patients, nurses, pharmacists, relatives or carers. It stands to reason that any measures which reduce confusion must be beneficial to our patients.
Secondly, the very tradition that we traditionalists long to cling to no longer exists. The United Kingdom adopted these changes in 2003. Many other countries, including New Zealand, have already adopted the INN nomenclature.
Australia has if anything been notable by its continued use of terminology considered out-of-date in international circles.
Thirdly, the use of standardised drug names confers multiple benefits for health practitioners, for drug manufacturers and for regulatory authorities. These include again reducing confusion, as well as eliminating the need for duplication of paperwork for licencing and registration, marketing, trial results, and import and export of medication.
Finally, those who succeed the current generation of clinicians and researchers will have no romantic attachment to the language of the past; an academic journal should embrace the nomenclature that its future authors and readers will use.
The Editorial Board of Anaesthesia and Intensive Care has thus resolved to support the TGA directive. From January 2017, the editorial team will gradually adopt the new drug names, with a view to complete compliance by January 2018.
Vale lignocaine … hail lidocaine. A full list of the new drug nomenclature is available at https://www.tga.gov.au/updating-medicine-ingredient-nameslist-affected-ingredients.
Interested readers are directed to the TGA Regulation impact statement, listed as reference 2.
